title: PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.
abstract: Imaging plays an important role in the clinical management of cancer patients. Hybrid imaging with PET/computed tomography (CT) is having a broad impact in oncology, and in recent years PET/CT is beginning to have an impact in urooncology. In both bladder and renal cancers, there is a need to study the efficacy of other tracers than F-18 fluorodeoxyglucose (FDG), particularly tracers with limited renal excretion. Thus, new tracers are being introduced. This review focuses on the clinical role of FDG and other PET agents in renal, bladder, and testicular cancers.
authors.affiliation: Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Skejby, Brendstrupgaardsvej 100, Aarhus DK-8200, Denmark. Electronic address: kirsbouc@rm.dk.
authors.forename: Kirsten
authors.initials: K
authors.lastname: Bouchelouche
authors.affiliation: Molecular Imaging Program, Building 10, Room B3B6B9F, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, MD, USA.
authors.forename: Peter L
authors.initials: PL
authors.lastname: Choyke
mesh_terms: D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging* / Q000473:pathology; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D008297:Male; D064847:Multimodal Imaging / Q000379:methods; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D019275:Radiopharmaceuticals; D013736:Testicular Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D014057:Tomography, X-Ray Computed / Q000379:methods*; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: Bladder cancer; PET/CT; Renal cancer; Testicular cancer